0
Dozens of mutations in the spike protein of the Omicron variant help it to evade all four of the classes of antibodies that can target SARS-CoV-2, according to a new study. This includes antibodies generated by the immune systems of vaccinated or previously infected people, as well as most of the monoclonal antibody treatments that have been developed.